Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension

10openopenKonstas A.G.; Quaranta L.; Katsanos A.; Riva I.; Tsai J.C.; Giannopoulos T.; Voudouragkaki I.C.; Paschalinou E.; Floriani I.; Haidich A.B.Konstas, A. G.; Quaranta, Luciano; Katsanos, A.; Riva, Ivano; Tsai, J. C.; Giannopoulos, T.; Voudouragkaki, I. C.; Paschalinou, E.; Floriani, I.; Haidich, A. B

Current perspectives on the use of anti-VEGF drugs as adjuvant therapy in glaucoma

The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments

Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma

8openopenKonstas A.G.; Quaranta L.; Mikropoulos D.G.; Nasr M.B.; Russo A.; Jaffee H.A.; Stewart J.A.; Stewart W.C.Konstas, A. G.; Quaranta, Luciano; Mikropoulos, D. G.; Nasr, M. B.; Russo, A.; Jaffee, H. A.; Stewart, J. A.; Stewart, W. C

Combined Pupilloplasty and Retropupillary Iris-Claw Intraocular Lens Implantation with DSAEK in a Patient with Traumatic Iridoplegia, Aphakia and Corneal Decompensation.

To report the management of a patient with traumatic mydriasis, aphakia and corneal decompensation with a triple procedure: simultaneous pupilloplasty and retropupillary iris-claw intraocular lens (IOL) implantation combined with Descemet stripping automated endothelial keratoplasty (DSAEK). An 88-year-old woman was referred to our Institute for consultation on her left eye. The patient had undergone surgical removal of the IOL, without re-implantation, in her left eye 10 months prior to presentation due to traumatic IOL dislocation. At the time of examination, corrected distance visual acuity was counting fingers and intraocular pressure was 10 mmHg. Slit-lamp examination revealed iridoplegia, aphakia and corneal edema. The patient underwent simultaneous pupilloplasty and retropupillary iris-claw IOL implantation combined with DSAEK. Six months postoperatively, the corneal graft was attached and clear, the iris was well reconstructed and almost round, and the iris-claw IOL was in place. Simultaneous pupilloplasty and retropupillary iris-claw IOL implantation combined with DSAEK was shown to be a safe surgical technique in a patient with traumatic mydriasis, aphakia and corneal decompensation